Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study

Investigational New Drugs

Volumn 29, Issue 4, 2011, Pages 680-687

  Ho, Cheryl ^a   Sangha, Randeep ^b   Beckett, Laurel ^c   Tanaka, Michael ^c   Lau, Derick H ^c   Eisen, Daniel B ^c   Burich, Rachel A ^c   Luciw, Paul ^c   Khan, Imran ^c   Mack, Philip C ^c   Gandara, David R ^c   Davies, Angela M ^d  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OSI PHARMACEUTICALS INC   (United States)

Author keywords

Acne lesion counting; Acneiform rash; Cetuximab; Global acne grading scale; Solid tumors

Indexed keywords

CETUXIMAB; CHEMOKINE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ACNE; ACNE LESION COUNTING; ADULT; AGED; ANEMIA; ANOREXIA; ANUS CARCINOMA; ARTICLE; BILE DUCT CARCINOMA; BLADDER TUMOR; BREAST TUMOR; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL TUMOR; CONSTIPATION; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRY SKIN; ESOPHAGUS TUMOR; FATIGUE; FEMALE; FIBROSARCOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GALLBLADDER TUMOR; GENE MUTATION; GLOBAL ACNE GRADING SCALE; HEAD AND NECK TUMOR; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; INFECTION; LEUKOPENIA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MESOTHELIOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA; ONCOGENE K RAS; OVARY TUMOR; PAIN; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE TUMOR; PRURITUS; RATING SCALE; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; THROMBOCYTOPENIA;

ACNE VULGARIS; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOKINES; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; SKIN; TREATMENT OUTCOME;

EID: 79959697579     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9396-4     Document Type: Article

References (15)

1. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787-2799 (Pubitemid 46606324)
2. Tos APD, Ellis I (2005) Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? Eur J Cancer 41:1383-1392
3. Fan Z, Masui H, Altas I et al (1993) Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53:4322-4328 (Pubitemid 24146785)
4. Sato JD, Kawamoto T, Le AD et al (1983) Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1:511-529
5. Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23:5235-5246 (Pubitemid 46224035)
6. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205-216
7. Witkowski JA, Parish LC (1999) From other ghosts of the past: acne lesion counting. J Am Acad Dermatol 40:131 (Pubitemid 29051046)
8. Lucky AW, Barber BL, Girman CJ et al (1996) A multirater validation study to assess the reliability of acne lesion counting. J Am Acad Dermatol 35:559-565 (Pubitemid 26427057)
9. Doshi A, Zaheer A, Stiller MJ (1997) A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol 36:416-418
10. Khan IH, Krishnan VV, Ziman M et al (2009) A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. Cytometry B Clin Cytom 76:159-168
11. US Department of Health and Human Services: Common terminology criteria for adverse events (CTCAE) version 3.0. National Institutes of Health, National Cancer Institute, 2003
12. Jonker DJ, O'Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048 (Pubitemid 350106711)
13. Koza I Sr, Wrba F, Vrbanec D et al (2009) Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 + cetuximab (FX+C) or FOLFIRI + cetuximab (FF+C): The CECOG/CORE1.2.001 trial. ASCO Meeting Abstracts 27:4055
14. Burtness B, Goldwasser MA, Flood W et al (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in Metastatic/Recurrent head and neck cancer: an eastern cooperative oncology group study. J Clin Oncol 23:8646-8654 (Pubitemid 46211507)
15. Saltz L, Kies M, Abbruzzese L et al (2003) The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22:204